/XTLB
XTLB Stock - XTL Biopharmaceuticals Ltd.
Healthcare|BiotechnologyNASDAQ
$0.82+0.88%
+$0.01 (+0.88%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.3
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.83
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XTLB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.81 – $0.83
TARGET (TP)$0.94
STOP LOSS$0.75
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.92
52W High$2.57
52W Low$0.76
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $451,000 | N/A | N/A | N/A | N/A |
| Gross Profit | $3,000 | N/A | $-1,000 | $-1,000 | $-1,000 |
| Gross Margin | 0.7% | N/A | N/A | N/A | N/A |
| Operating Income | $-2,172,000 | $-765,000 | $-880,000 | $-1,031,000 | $-948,000 |
| Net Income | $-1,027,000 | $-1,782 | $-1,348,000 | $435,000 | $-782,000 |
| Net Margin | -227.7% | N/A | N/A | N/A | N/A |
| EPS | $-0.15 | $0.00 | $-0.25 | $0.08 | $-0.57 |
Company Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XTLBBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$0.10
Q2 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 29, 2025 | — | — | — | — |
Q2 2025 | Jun 30, 2025 | — | $0.10 | — | — |
Q1 2025 | Jan 1, 2025 | — | $-0.04 | — | — |
Q4 2024 | Dec 30, 2024 | — | $-0.13 | — | — |
Q3 2024 | Sep 26, 2024 | — | $-0.07 | — | — |
Q2 2024 | May 13, 2024 | — | $0.10 | — | — |
Q1 2024 | Mar 27, 2024 | — | $-0.14 | — | — |
Q4 2023 | Nov 15, 2023 | — | $-0.04 | — | — |
Q3 2023 | Aug 10, 2023 | — | $-0.07 | — | — |
Q2 2023 | May 16, 2023 | — | $-0.17 | — | — |
Q1 2023 | Mar 22, 2023 | — | $-0.14 | — | — |
Q4 2022 | Nov 29, 2022 | — | $-0.15 | — | — |
Q3 2022 | Aug 24, 2022 | — | $-0.10 | — | — |
Q2 2022 | Jun 1, 2022 | — | $0.00 | — | — |
Q1 2022 | Mar 30, 2022 | — | $0.40 | — | — |
Q4 2021 | Nov 24, 2021 | — | $-0.00 | — | — |
Q3 2021 | Aug 24, 2021 | — | $-0.22 | — | — |
Q2 2021 | May 19, 2021 | — | $0.05 | — | — |
Q1 2021 | Mar 15, 2021 | — | $0.04 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.00 | — | — |
Frequently Asked Questions about XTLB
What is XTLB's current stock price?
XTL Biopharmaceuticals Ltd. (XTLB) is currently trading at $0.82 per share. The stock has moved +0.88% today.
What is the analyst price target for XTLB?
No analyst price targets are currently available for this stock.
What sector is XTL Biopharmaceuticals Ltd. in?
XTL Biopharmaceuticals Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XTLB's market cap?
XTL Biopharmaceuticals Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does XTLB pay dividends?
No, XTL Biopharmaceuticals Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIM
AIM ImmunoTech Inc.
$1.42
Mkt Cap: $0.0B
CYCN
Cyclerion Therapeutics, Inc.
$1.45
Mkt Cap: $0.0B
ENSC
Ensysce Biosciences, Inc.
$1.16
Mkt Cap: $0.0B
KALA
KALA BIO, Inc.
$0.62
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
PLRZ
Polyrizon Ltd.
$9.43
Mkt Cap: $0.0B
QNRX
Quoin Pharmaceuticals, Ltd.
$14.20
Mkt Cap: $0.0B
RADX
Radiopharm Theranostics Limited
$5.19
Mkt Cap: $0.0B
TCRT
Alaunos Therapeutics, Inc.
$3.56
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
Explore stocks similar to XTLB for comparison